IRLAB’s CEO intends to step down during the first quarter of 2027
Gothenburg, September 3, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announces today that Kristina Torfgård has informed the Board of Directors that she wishes to step down from her position as CEO. She will remain in the CEO role until the first quarter of 2027, creating good conditions for a smooth transition to her successor. The Board of Directors will immediately initiate the work to ensure a well-structured leadership transition.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
CEO interview with Kristina Torfgård and CFO Gustaf Albèrt at Redeye
Redeye interviewed CEO Kristina Torfgård and CFO Gustaf Albèrt about IRLAB’s announced rights issue and the company’s priorities going forward. Published on June 16, 2026. Watch the video on Vimeo
Read More >